COMPASS THERAPEUTICS, INC. (CMPX) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 180.09M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 180.09M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 180.09M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 180.09M | (m) | (m) |
| 2026-03-31 | 180.09M | (m) | (m) |
| 2025-12-31 | 180.09M | (m) | (m) |
| 2025-09-30 | 177.86M | (m) | (m) |
| 2025-06-30 | 138.28M | (m) | (m) |
| 2025-03-31 | 138.28M | (m) | (m) |
| 2024-12-31 | 138.28M | (m) | (m) |
| 2024-09-30 | 137.59M | (m) | (m) |
| 2024-06-30 | 137.59M | (m) | (m) |
| 2024-03-31 | 137.59M | (m) | (m) |
| 2023-12-31 | 137.59M | (m) | (m) |
| 2023-09-30 | 127.49M | (m) | (m) |
| 2023-06-30 | 127.46M | (m) | (m) |
| 2023-03-31 | 126.51M | (m) | (m) |
| 2022-12-31 | 126.51M | (m) | (m) |
| 2022-09-30 | 126.19M | (m) | (m) |
| 2022-06-30 | 101.28M | (m) | (m) |
| 2022-03-31 | 101.28M | (m) | (m) |
| 2021-12-31 | 101.30M | (m) | (m) |
| 2021-09-30 | 98.03M | (m) | (m) |
| 2021-06-30 | 61.69M | (m) | (m) |
| 2021-03-31 | 51.31M | (m) | (m) |
| 2020-12-31 | 52.11M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |